# Synthesis and Antitumor Potency of 2E,21E-bis-(2-Pyridinylidene)-hollongdione in NCI-60 Panel and Zebrafish Model

**Authors:** Irina Smirnova, Zarema Galimova, Alexander Lobov, Anastasiia Mikheenko, Irina Khan, Gulalek Babayeva, Vadim S. Pokrovsky, Oxana Kazakova

PMC · DOI: 10.3390/ijms27041813 · International Journal of Molecular Sciences · 2026-02-13

## TL;DR

A new compound was created and shown to effectively kill many cancer cell types, including melanoma, and work well in a zebrafish cancer model.

## Contribution

An efficient site-selective synthesis of potent anticancer dammarane-type chalcones and a promising bis-2-pyridylidene derivative with submicromolar potency.

## Key findings

- Bis-2-pyridylidene derivative 3 showed antitumor activity in 58 of 59 NCI-60 cancer cell lines.
- Compound 3 exhibited high selectivity for melanoma, renal, and prostate cancers with an SI of up to 18.82.
- In zebrafish xenograft models, compound 3 inhibited tumor growth by 72% without significant toxicity.

## Abstract

Michael acceptors, such as chalcones and benzylidenes, are privileged scaffolds for the development of anticancer agents. Taking this into account, we developed a selective Claisen–Schmidt condensation of the dammarane-type triterpenoid hollongdione with pyridine-2-carbaldehyde, enabling controlled synthesis of mono- and bis-substituted triterpenes depending on the reaction conditions. The reaction demonstrated high temperature-dependent regioselectivity, providing C2-mono- 2 or 2,21-bis-substituted 3 triterpenes with yields up to 96% and 95%, respectively. The structures of the newly synthesized triterpene chalcones were elucidated by 1D and 2D NMR spectroscopy and unambiguously confirmed by a single-crystal X-ray diffraction, which established the E configuration of the exocyclic double bond. In biological studies, the bis-2-pyridylidene derivative 3 exhibited a pronounced and broad-spectrum antitumor activity in the NCI-60 panel, inducing cell death in 58 of 59 cancer cell lines. High selectivity toward melanoma, renal, and prostate cancer cell lines was observed, with selectivity indices (SI) of up to 18.82 for melanoma LOX IMVI. In MTT assays, compound 3 displayed a submicromolar cytotoxicity, particularly against the KRAS-mutant PANC-1 cell line (IC50 = 0.22 µM). Anticancer activity was further confirmed in a zebrafish (Danio rerio) xenograft model of human HCT116 colon cancer, where tumor growth inhibition reached 72% without pronounced embryotoxicity (LC50 = 1.4 µM). We have developed an efficient approach for the site-selective modification of hollongdione, providing access to potent anticancer dammarane-type chalcones. The bis-2-pyridylidene derivative 3 emerged as a promising lead compound, demonstrating submicromolar potency, high selectivity towards melanoma, and significant in vivo efficacy in a zebrafish xenograft model.

## Linked entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Chemicals:** hollongdione (PubChem CID 15559638), pyridine-2-carbaldehyde (PubChem CID 14273), compound 3 (PubChem CID 20788885)
- **Diseases:** melanoma (MONDO:0005105), renal cancer (MONDO:0005206), prostate cancer (MONDO:0005159), colon cancer (MONDO:0002032)
- **Species:** Danio rerio (taxon 7955), Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** kras (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) [NCBI Gene 445289] {aka K-ras, fa04e08, fc14b12, fc23g10, fj89d12, wu:fa04e08}, DCTN6 (dynactin subunit 6) [NCBI Gene 10671] {aka WS-3, WS3, p27}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, NQO1 (NAD(P)H quinone dehydrogenase 1) [NCBI Gene 1728] {aka DHQU, DIA4, DTD, NMOR1, NMORI, QR1}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CCNA2 (cyclin A2) [NCBI Gene 890] {aka CCN1, CCNA}, CCNE1 (cyclin E1) [NCBI Gene 898] {aka CCNE, pCCNE1}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, HMHB1 (histocompatibility minor HB-1) [NCBI Gene 57824] {aka HB-1, HB-1Y, HLA-HB1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CYP1A2 (cytochrome P450 family 1 subfamily A member 2) [NCBI Gene 1544] {aka CP12, CYPIA2, P3-450, P450(PA)}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, KRT31 (keratin 31) [NCBI Gene 3881] {aka HA1, Ha-1, KRTHA1, hHa1}, loxa (lysyl oxidase a) [NCBI Gene 404621] {aka lox, zgc:77447}, LOX (lysyl oxidase) [NCBI Gene 4015] {aka AAT10}, CYP2C9 (cytochrome P450 family 2 subfamily C member 9) [NCBI Gene 1559] {aka CPC9, CYP2C, CYP2C10, CYPIIC9, P450-2C9, P450IIC9}, HSD17B1 (hydroxysteroid 17-beta dehydrogenase 1) [NCBI Gene 3292] {aka 17-beta-HSD, 20-alpha-HSD, E2DH, EDH17B2, EDHB17, HSD17}
- **Diseases:** CNS cancer (MESH:D009369), lung cancer (MESH:D008175), melanoma, renal, and prostate cancer (MESH:D011471), colon, CNS, renal, and melanoma (MESH:D008545), inflammation (MESH:D007249), neurodegenerative diseases (MESH:D019636), injury to (MESH:D014947), developmental abnormalities and delays (MESH:D006130), pancreatic cancer (MESH:D010190), renal cancer (MESH:D007680), spinal deformities (MESH:D013122), hypoxia (MESH:D000860), colon carcinoma (MESH:D003110), organ failure (MESH:D009102), lethality (MESH:C536057), Cytotoxicity (MESH:D064420), leukemia (MESH:D007938), colon cancer (MESH:D015179), NSC (OMIM:617394), liver cancer (MESH:D006528), glioblastoma (MESH:D005909), breast cancer (MESH:D001943), hypersensitivity (MESH:D004342), melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers (MESH:D010051)
- **Chemicals:** C4 (MESH:C058899), N (MESH:D009584), tetramethylsilane (MESH:C073196), CO (MESH:D002248), C (MESH:D002244), streptomycin (MESH:D013307), C14 (MESH:C000615234), hydroxamic acid (MESH:D006877), NaCl (MESH:D012965), Hollongdione (MESH:C000722856), 3H (MESH:D014316), Methanol (MESH:D000432), 1,3-diphenyl-2-propen-1-one (MESH:D002599), acetanilide (MESH:C508827), H3- (MESH:C012616), chalcones (MESH:D047188), formazan (MESH:D005562), Belinostat (MESH:C487081), Oxygen (MESH:D010100), pyridine-2-carbaldehyde (MESH:C432864), HCl (MESH:D006851), beta-boswellic acid (MESH:C054625), CaCl2 (MESH:D002122), CFSE (MESH:C087165), aldehyde (MESH:D000447), platanic acid (MESH:C087107), C15 (MESH:C003946), mono- (MESH:C106553), NaOH (MESH:D012972), 13C (MESH:C000615229), dammarane (MESH:C102963), oxaliplatin (MESH:D000077150), EtOH (MESH:D000431), 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (MESH:C000718175), methylene blue (MESH:D008751), H2O (MESH:D014867), 5-FU (MESH:D005472), petroleum ether (MESH:C004544), C6 (MESH:C117224), Al2O3 (MESH:D000537), 2-pyridinecarboxaldehyde (MESH:C522921), V (MESH:D014639), MTT (MESH:C070243), thiol (MESH:D013438), triterpene (MESH:D014315), 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MESH:C022616), S (MESH:D013455), ozone (MESH:D010126), 2,21-bis-[3-pyridinyl]-methylidenohollongdione 3 (-), graphite (MESH:D006108), ethyl acetate (MESH:C007650), penicillin (MESH:D010406), pyridine (MESH:C023666), DRB (MESH:D004317), SiO2 (MESH:D012822), quinone (MESH:C004532), MO (MESH:D008982), H (MESH:D006859), C21 (MESH:C000711730), PBS (MESH:D007854)
- **Species:** Danio (genus) [taxon 7954], Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955], Actinopterygii (fishes, superclass) [taxon 7898]
- **Mutations:** V600E, G12D, C12, C for 2-3, G12C
- **Cell lines:** NCI-60 — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_A592), SNB-19 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0535), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), OVCAR-4 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_1627), MDA-MB-435-3M — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0417), RXF — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1673), MIA PaCa-2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428), CCDC 966944 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_SH25), IMVI — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_1381), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HS-578T — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0332), HOP-92 — Homo sapiens (Human), Lung non-small cell carcinoma, Cancer cell line (CVCL_1286), DU-145 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0105), MOLT-4 — Homo sapiens (Human), Adult T acute lymphoblastic leukemia, Cancer cell line (CVCL_0013), UCC-62 — Homo sapiens (Human), Ataxia telangiectasia syndrome, Transformed cell line (CVCL_ZT65), NCI-H522 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_1567), 786-0 — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1051), HCT-116 — Homo sapiens (Human), Colon carcinoma, Cancer cell line (CVCL_0291), DU — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_5528), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), T-47D — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0553), NCI — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0078), Huh7 — Homo sapiens (Human), Adult hepatocellular carcinoma, Cancer cell line (CVCL_0336), U-31 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184), SKBR-3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033), NCI-H226 — Homo sapiens (Human), Pleural epithelioid mesothelioma, Cancer cell line (CVCL_1544), UACC-257 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_1779), BT-549 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_1092), SW620 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0547), HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320), 1BR3 — Homo sapiens (Human), Finite cell line (CVCL_2279), HL(60)-TB — Homo sapiens (Human), Adult acute myeloid leukemia with maturation, Cancer cell line (CVCL_A794), CCRF-CEM — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0207), SK-MEL-5 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0527), SK-OV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), HCC-2998 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_1266), SK-MEL-2 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_0069), PC-3 — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0035), A498 — Homo sapiens (Human), Renal cell carcinoma, Cancer cell line (CVCL_1056), SK-MEL-28 — Homo sapiens (Human), Cutaneous melanoma, Cancer cell line (CVCL_0526), OVCAR-5 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_1628), PANC-1 — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_0480), U-251 — Homo sapiens (Human), Astrocytoma, Cancer cell line (CVCL_0021), OVCAR-3 — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_0465)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12941353/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12941353/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC12941353/full.md

---
Source: https://tomesphere.com/paper/PMC12941353